MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT). The usual treatment for prostate cancer that has spread to other parts of the body is to give lifelong treatment with hormone therapy (also known as androgen deprivation therapy or ADT). Participants may also be given prostate RT even if the disease is metastatic. Participants will receive hormone therapy (the standard treatment for prostate cancer) for 12 months. The hormone therapy agents may be taken by mouth or given as an injection. Participants will also have prostate RT. Up to 50 participants will have surgery to remove the prostate instead of having prostate RT. A portion of the participants will be randomized to receive MDRT to areas where the cancer has spread. For participants who have surgery to remove their prostate, they will be asked to allow tissue samples collected during the surgery to be sent to an outside lab for research tests and extra blood samples drawn for research tests before starting the study, and at the time the cancer becomes worse if applicable. Participation in the study will last approximately 12 months, and will be followed by their doctor for up to five years per standard of care. The main goal is to compare the efficacy of the standard of care (standard systemic therapy + definitive prostate-directed local therapy) versus the standard of care with metastasis-directed radiotherapy (MDRT) for consolidation of metastatic disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi mieć ukończone 18 lat.
- •Ogólny stan zdrowia pacjenta musi być dobry (pozwala na normalną aktywność z pewnymi ograniczeniami).
- •Rak prostaty musi być potwierdzony badaniem histologicznym i widoczny na obrazach (np. rezonans, tomografia, scyntygrafia lub PET-CT z PSMA) jako choroba, która się rozprzestrzeniła.
- •Choroba musi być zdiagnozowana niedawno, bez wcześniejszego leczenia (operacji, radioterapii, hormonoterapii ani chemioterapii).
- •Pacjent mógł rozpocząć leczenie hormonalne, ale nie wcześniej niż 30 dni przed włączeniem do badania.
- •Jeśli choroba rozprzestrzeniła się w kościach lub węzłach chłonnych (poza miednicą), ale w niewielkiej liczbie (1-5 ognisk) widocznych na standardowych badaniach obrazowych.
- •Jeśli wykonano PET-CT z PSMA, ograniczona ilość ognisk (1-10) widocznych w kościach lub węzłach chłonnych (poza miednicą) może kwalifikować pacjenta do badania.
✗ Disqualifies
- •Przed rozpoczęciem badania pacjent nie może być wcześniej leczony na raka prostaty (operacja, radioterapia, hormonoterapia, chemioterapia) – z wyjątkiem rozpoczętego niedawno leczenia hormonalnego.
- •Pacjenci, u których choroba rozprzestrzeniła się do węzłów chłonnych w miednicy, a nie poza nią, chyba że spełniają dodatkowe kryteria.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (2)
University Hospitals Cleveland Medical Center Seidman Cancer Center
Cleveland, United States
Carbone Cancer Center University of Wisconsin-Madison
Madison, United States
Trial contact
Angela Y Jia, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.